Unit launches study to monitor COVID-19 in 12,000 Cambridgeshire residents - July 2020

Participants in Cambridgeshire's Fenland Study are being invited to join an innovative study that will use a home-administered blood sampling device - the Drawbridge Health OneDraw device - to find out how many have evidence in their blood of previous COVID-19 infection. The primary aim of this study is to quantify the proportion of people who have had COVID-19 in the Fenland cohort, and participants will be tested several times over the duration of the study allow researchers to identify new as well as existing COVID-19 cases. Researchers will also be able to determine if those with COVID-19 antibodies at the start of the study continue to have positive antibody status over the study period, or if antibody levels decline over time. The study will also investigate whether it is possible to identify the COVID-19 pre-symptomatic phase using measurement of signs and symptoms collected via a smartphone App developed by Huma. Participants will use a smartphone app to record measurements such as heart rate, heart rate variability, respiratory rate, blood oxygen, and temperature. Participants will also enter health information such as body weight and diet changes, medication and supplement use, their mental health and wellbeing, and COVID-19 symptoms and potential risk factors.